AstraZeneca Pays $50 Million For Rights To Merck Cancer Drug

Wochit
Merck has licensed its experimental cancer drug to AstraZeneca for a $50 million upfront fee in a deal that shows Britain's second-biggest drugmaker continuing to rebuild its pipeline.
View Comments (0)